MBI to begin phase-III trials for FS069

Researchers noted a 20.1 percent incidence of bone-only metastasis in a cohort of men with castration-resistant prostate cancer, according to findings from research presented at the recent Society for Nuclear Medicine and Molecular Imaging (SNMMI) conference.

In the third episode of a three-part podcast, Anand Narayan, M.D., Ph.D., and Amy Patel, M.D., discuss the challenges of expanded breast cancer screening amid a backdrop of radiologist shortages and ever-increasing volume on radiology worklists.

For patients discharged from the hospital with confirmed COVID-19, median five-month follow-up MRI findings revealed a greater likelihood of regional brain volume reduction, parenchymal lung abnormalities and loss of corticomedullary differentiation in the kidney in comparison to people who have not had COVID-19.

In the second episode of a three-part podcast, Anand Narayan, M.D., Ph.D., and Amy Patel, M.D., discuss recent studies published by the Journal of the American Medical Association (JAMA) that suggested moving to more of a risk-adapted model for mammography screening.

The Exo Iris reportedly combines advanced silicon technology with imaging, workflow software and artificial intelligence (AI) to facilitate multidisciplinary use of point-of-care ultrasound.

The transitional pass-through payment reimbursement code for the FDA-approved PSMA PET agent for prostate cancer detection will be effective as of October 1, according to the Centers for Medicare and Medicare Services (CMS).